An integrative neuropharmacological review of Huntington’s disease challenges and the role of novel formulations in addressing pharmacological‒pharmaceutical limitations
Mahmoud A. Senousy, Aya H. Eid, Mohamed Bakr Zaki, Mai A. Abd-Elmawla, Heba R. Ghaiad, Riham A. El-Shiekh, Sadek Ahmed, Hazim O. Khalifa · 2026
Read An integrative neuropharmacological review of Huntington’s disease challenges and the role of novel formulations in addressing pharmacological‒pharmaceutical limitations by Mahmoud A. Senousy, Aya H. Eid, Mohamed Bakr Zaki, Mai A. Abd-Elmawla, Heba R. Ghaiad, Riham A. El-Shiekh, Sadek Ahmed, Hazim O. Khalifa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13190188.txt.
Description
Mahmoud A Senousy and co-authors review Huntington disease and the drug delivery problems it poses. Their 2026 review covers an inherited brain disease caused by a repeated stretch in the huntingtin gene. The disease slowly harms nerve cells, most visibly in deep brain areas tied to movement.
The authors stress that the disease reaches beyond the brain, into the rest of the body as well. That wider view shapes when the disease starts, how it moves, and how patients differ. The review links brain science with drug making, with a focus on new formulas that can carry drugs past barriers. Nano-based carriers get special attention. The aim is a single account that joins what the disease does with how new treatments might reach their targets.
Catalog record
| CREATOR | Mahmoud A. Senousy, Aya H. Eid, Mohamed Bakr Zaki, Mai A. Abd-Elmawla, Heba R. Ghaiad, Riham A. El-Shiekh, Sadek Ahmed, Hazim O. Khalifa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 114 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |